| General Information of Drug Metabolite (DM) (ID: DM017940) |
| DM Name |
TAK-438 N-sulfate
|
| Structure |
|
|
3D MOL is unavailable
|
2D MOL is unavailable
|
|
|
|
|
|
|
|
| Full List of Drug-Metabolizing Enzyme (DME) Related to This DM |
| DME(s) Producing This DM through Metabolism |
| DME Name |
DME ID |
Reactant |
Reaction |
Related Drug |
REF |
|
Sulfotransferase 2A1 (SULT2A1)
|
DME0074
|
| Oxidation - Sulfonation |
Vonoprazan
|
[1] , [2] |
|
|
|
|
|
|
|
| DME(s) Metabolizing This DM |
| DME Name |
DME ID |
Product |
Reaction |
Related Drug |
REF |
|
Cytochrome P450 2C9 (CYP2C9)
|
DME0019
|
| Oxidation - Hydroxylation |
Vonoprazan
|
[1] , [2] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Full List of Drug(s) That Produce This DM By Metabolism |
| Vonoprazan |
DR1705
|
Phase 4 |
Gastro-oesophageal reflux disease |
|
|
| References |
| 1 |
Vonoprazan fumarate, a novel potassium-competitive acid blocker, in the management of gastroesophageal reflux disease: safety and clinical evidence to date
|
| 2 |
In vitro metabolism of TAK-438, vonoprazan fumarate, a novel potassium-competitive acid blocker. Xenobiotica. 2017 Dec;47(12):1027-1034.
|
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.
